Gujarat Themis Biosyn Q1 FY27 Results: Net Profit ₹1,106.67 Lakh
Gujarat Themis Biosyn reported Q1 FY27 results with total income at ₹4,392.16 lakh and net profit at ₹1,106.67 lakh. EPS stood at ₹1.02. The company also incorporated two subsidiaries outside India, though they have no operational impact yet.
The announcement includes financial results which are material for investors. The incorporation of subsidiaries also indicates strategic moves for future expansion.
The company reported positive financial results with increased net profit compared to the previous quarter, and the incorporation of subsidiaries, despite no immediate operational impact, suggests future growth potential.
Gujarat Themis Biosyn Limited announced its Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors approved these results during a meeting that commenced at 10:30 A.M. (IST) and concluded at 12:55 P.M. (IST) on August 7, 2026.
For the quarter ended June 30, 2026, the company reported a total income of ₹4,392.16 lakh. Total expenses amounted to ₹2,875.63 lakh, leading to a profit before tax of ₹1,516.53 lakh. The net profit after tax stood at ₹1,106.67 lakh, with earnings per share (basic and diluted) at ₹1.02.
In the consolidated results, the figures for total income and net profit after tax were also ₹4,392.16 lakh and ₹1,106.67 lakh, respectively. The company noted the incorporation of two wholly-owned subsidiaries outside India: Themis Biosyn Japan Limited and Themis Biosyn Ireland Private Limited. However, as these entities have not yet commenced operations and no capital has been remitted, there is no impact on the consolidated financial results for this quarter. The comparative financial information for previous periods represents previously reported standalone data.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.